GET DAILY SIGNALSFMC Corporation (FMC) Reports Deep Q3 2026 Revenue Decline Amid Portfolio Shift
Key Takeaways
- FMC Corporation reported third quarter 2026 revenue of $106 million, an 80% decline year over year that came in far below Wall Street expectations.
- The company posted a GAAP (generally accepted accounting principles) net loss of $2.07 billion, or $15.54 per diluted share, versus a $569 million loss in the prior-year period.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) swung to negative $559 million, weighed down by a $672 million impact from intentional commercial actions.
- A $639 million revenue impact from commercial actions, combined with weaker-than-expected demand, drove the quarterly shortfall.
- Fourth quarter 2026 revenue guidance was set at $1.04 billion to $1.14 billion, with the midpoint roughly flat versus the fourth quarter of 2025.
- Management said its priority is now "disciplined execution with our customers" as it works through its post-patent and portfolio transformation.
- For more context on this ticker, explore FMC's Major News, Today's Price Move, Price Targets, and Forecast on dedicated analysis pages.
- Interested in broader market opportunities? Explore Trending AI Robots to see automated strategies currently drawing attention from traders.
Earnings Context and Why It Matters
FMC Corporation is an agricultural sciences company whose crop protection portfolio has been undergoing a difficult transition as its flagship Rynaxypyr® active ingredient moves past patent protection and as the company executes a series of strategic divestitures. Those efforts, including the planned sale of its India commercial business and other asset monetizations aimed at debt reduction, have produced substantial non-cash charges and disrupted near-term revenue. For investors, this report matters because it tests whether management's restructuring can stabilize the business and return it to growth. The quarter's massive top-line shortfall and deepening losses signal that the transition is proving more painful than anticipated, raising fresh questions about cash generation and the balance sheet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
FMC reported third quarter 2026 revenue of $106 million, down 80% from $542 million a year earlier and dramatically below analyst consensus. Management attributed the decline primarily to a $639 million revenue impact from commercial actions, alongside weaker-than-expected customer demand.
On a GAAP basis, the company recorded a net loss of $2.07 billion, or $15.54 per diluted share, compared with a loss of $569 million, or $4.52 per share, in the third quarter of 2025. Adjusted EBITDA fell to negative $559 million from positive $236 million a year ago, reflecting a $672 million negative impact from commercial actions.
Free cash flow was negative $18 million, an improvement of $214 million year over year, driven by favorable working capital dynamics despite cash outflows for restructuring. For the fourth quarter, FMC guided to revenue of $1.04 billion to $1.14 billion, with a midpoint roughly stable compared with the prior-year period.
Market Reaction and Investor Sentiment
Sentiment around FMC has deteriorated sharply over the past year as the post-patent transition and restructuring charges have eroded earnings. The stock has already fallen steeply in 2026, and this quarter's results — which missed estimates by a wide margin — reinforced investor concerns about demand and execution. Elevated short interest signals that a meaningful portion of the market remains positioned for further downside, while the combination of heavy non-cash charges and negative adjusted EBITDA underscores the pressure on profitability. The weak quarter, paired with a full-year outlook revised lower, suggests the market is likely to remain cautious until FMC demonstrates sustained stabilization in revenue and cash flow.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether FMC can deliver the fourth quarter revenue recovery embedded in its guidance of $1.04 billion to $1.14 billion. Management expects volume growth to return, helped by increased direct sales to growers in Brazil, new active ingredients, and North America distributor orders that shifted from the third quarter into the fourth.
Key factors to monitor include the progress of the Rynaxypyr® post-patent strategy and whether pricing stabilizes after the planned commercial actions. The completion of asset sales — including the India divestiture and other monetizations intended to fund roughly $1 billion in debt reduction — will be critical for the balance sheet.
Investors should also watch free cash flow trends, interest expense, and any further restructuring costs, as these will determine how quickly FMC can return to profitability. Demand signals across agricultural end markets and distributor inventory behavior will remain important swing factors in the quarters ahead. From what I see, tracking these elements with tools like Tickeron’s AI Trend Prediction Engine can help clarify the path forward.
Using Tickeron’s AI Screener for Deeper Analysis
In my own research process, I turned to Tickeron’s AI Screener to quickly filter agricultural stocks and compare fundamentals, technical signals, and performance metrics. It helped surface relevant peers and highlighted how FMC stacks up on volatility and trend factors. This kind of scan saves time while pointing to setups that might warrant closer review, especially during periods of sector transition.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FMC's Indicator enters downward trend
The Aroon Indicator for FMC entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator formed such a pattern. In 164 of the 223 cases the stock moved lower. This puts the odds of a downward move at 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMC advanced for three days, in 177 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
FMC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.425) is normal, around the industry mean (-0.351). P/E Ratio (-0.203) is within average values for comparable stocks, (8.658). Projected Growth (PEG Ratio) (1.532) is also within normal values, averaging (0.867). Dividend Yield (0.072) settles around the average of (0.126) among similar stocks. P/S Ratio (0.416) is also within normal values, averaging (1.476).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. FMC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FMC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of industrial, specialty and agricultural chemicals
Industry ChemicalsAgricultural
Advertisement